Filter
Exclude
Time range
-
Near
Don’t miss your chance to enroll. SWTX Summer and Fall 2026 registration is now open, so it's time to secure your classes and stay on track. GET STARTED: bit.ly/4sIcQ7e
16
$PBLS 3.7B MC Good story but too expensive $SWTX was aquired for 3.4B, 1.5y after nirogacestat approval in desmoid PBLS will start ph3 in desmoid in h1'27. Other trails are in early ph1. Hard pass
$PBLS IPO today MC at ipo price of 20 will be 2.2B. 110M shares. 4.2M shares owned by $REGN Top drug to enter ph3 in h1'27
1
12
3,058
I'm not super familiar with their data but if the ph2 desmoid tumor looks good, I assume someone is out there figuring that SWTX looks vulnerable and that location alone could be worth 4-6B for a good drug
1
89
Replying to @doepke_michel
Different MOA cmt $SWTX and $IMNM. Reported high ORR so far
3
522
$PBLS The most advanced program targets desmoid tumors. Relevant for $IMNM ($2.1B MC) and $SWTX (bought by MerckKGaA for $3.4B). The IPO seems a bit overpriced to me, but the $REGN investment is a strong sign. Parabilis is added to the watchlist.
$PBLS IPO today MC at ipo price of 20 will be 2.2B. 110M shares. 4.2M shares owned by $REGN Top drug to enter ph3 in h1'27
1
13
4,150
Ditto $insm .. another case of mis-mgmt of analysts / expectations / comms joining the likes of $slno $apls $gern $iova $swtx ( $abvx and $cytk (Blum may have turned corner)) .. all unique sits/ TAs but consistent variable is you (investor) listen to conference call / presentation and say “would love to have been fly-on-wall when they decided that was good idea”
$insm maybe Will Lewis should spend less time on space travel and more time managing analyst / investor expectations With that said, is Insmed vulnerable down here??
6
4,138